Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rowan G. Bullock"'
Autor:
Gerard P. Reilly, Charles J. Dunton, Rowan G. Bullock, Daniel R. Ure, Herbert Fritsche, Srinka Ghosh, Todd C. Pappas, Ryan T. Phan
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundConservative management of adnexal mass is warranted when there is imaging-based and clinical evidence of benign characteristics. Malignancy risk is, however, a concern due to the mortality rate of ovarian cancer. Malignancy occurs in 10–
Externí odkaz:
https://doaj.org/article/c5b77441772d4123a3b527e4f1609ed0
Autor:
Charles J. Dunton, Megan L. Hutchcraft, Rowan G. Bullock, Lesley E. Northrop, Frederick R. Ueland
Publikováno v:
Diagnostics, Vol 11, Iss 8, p 1440 (2021)
Background: Ovarian cancer is the deadliest gynecologic cancer, with no recommended screening test to assist with early detection. Cancer antigen 125 (CA125) is a serum biomarker commonly used by clinicians to assess preoperative cancer risk, but it
Externí odkaz:
https://doaj.org/article/076c2f1465c84d2a82c05330d4831023
Autor:
Herbert A. Fritsche, Rowan G. Bullock
Publikováno v:
International Journal of Gynecology & Obstetrics.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de325ce20b90a03a8f142aa669c0d0df
https://doi.org/10.1002/ijgo.14733
https://doi.org/10.1002/ijgo.14733
Autor:
Gerard Reilly, Rowan G. Bullock, Jessica Greenwood, Daniel R. Ure, Erin Stewart, Pierre Davidoff, Justin DeGrazia, Herbert Fritsche, Charles J. Dunton, Nitin Bhardwaj, Lesley E. Northrop
Publikováno v:
JCO clinical cancer informatics. 6
PURPOSE Early detection of ovarian cancer, the deadliest gynecologic cancer, is crucial for reducing mortality. Current noninvasive risk assessment measures include protein biomarkers in combination with other clinical factors, which vary in their ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7859caac4487fa3b8d4f6ea822c641c7
https://pubmed.ncbi.nlm.nih.gov/35671415
https://pubmed.ncbi.nlm.nih.gov/35671415
Publikováno v:
Advances in Therapy
Introduction Adnexal or pelvic mass is a finding that commonly raises suspicion for malignancy, especially for ovarian cancer. Proper identification prior to surgery would permit appropriate referral to a specialty center in cases likely to be ovaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a79dca828175fde131393c5990d7744e
https://doi.org/10.1007/s12325-019-01010-8
https://doi.org/10.1007/s12325-019-01010-8
Publikováno v:
Current medical research and opinion. 36(12)
To assess the use of Multivariate Index Assay (MIA OVA1) by gynecologists and determine referral practices and surgical decision making for women with adnexal masses and low-risk MIA OVA1 scores.Information on patients who received an OVA1 test was c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5740ff4066cb89b4c0086d50e1875d4d
https://pubmed.ncbi.nlm.nih.gov/33107342
https://pubmed.ncbi.nlm.nih.gov/33107342
Autor:
Todd C. Pappas, Donald G. Munroe, Kathy Agnew, Vinicius Bonato, Rowan G. Bullock, Renata R. Urban, Barbara A. Goff
Publikováno v:
Gynecologic Oncology. 150:318-323
To assess the performance of a symptom index (SI) and multivariate biomarker panel in the identification of ovarian cancer in women presenting for surgery with an adnexal mass.Prospective study of patients seen at a tertiary medical center. Following
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19eb5bc27540b1d7458e6a12ac9effe1
https://doi.org/10.1016/j.ygyno.2018.06.004
https://doi.org/10.1016/j.ygyno.2018.06.004